Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy

Overview

MYRE is a phase III multicentric controlled national clinical trial conducted in patients with multiple myeloma and renal failure related to myeloma cast nephropathy (MCN). Its aims are to assess (1) the efficacy of bortezomib plus dexamethasone (BD), compared with cyclophosphamide, plus bortezomib and dexamethasone (C-BD) in patients with inaugural MCN not requiring hemodialysis; and (2) in patients with inaugural severe renal failure secondary to biopsy-proven MCN and requiring hemodialysis that of an intensive hemodialysis regimen using either a dialyser with very high permeability to proteins (TheraliteTM) or a conventional high-flux dialyser, while receiving chemotherapy with BD.

Full Title of Study: “Treatment of Renal Failure Due to Myeloma Cast Nephropathy: Comparison of Two Different Chemotherapy Regimens and Evaluation of Optimized Removal of Monoclonal Immunoglobulin Light Chains Using a High Permeability Hemodialysis Membrane.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 2015

Detailed Description

MYRE is a phase III multicentric controlled national clinical trial conducted in patients with multiple myeloma and renal failure related to myeloma cast nephropathy (MCN). Its aims are to assess (1) the efficacy of bortezomib plus dexamethasone (BD), compared with cyclophosphamide, plus bortezomib and dexamethasone (C-BD) in patients with inaugural MCN not requiring hemodialysis; and (2) in patients with inaugural severe renal failure secondary to biopsy-proven MCN and requiring hemodialysis that of an intensive hemodialysis regimen using either a dialyser with very high permeability to proteins (TheraliteTM) or a conventional high-flux dialyser, while receiving chemotherapy with BD. Study hypotheses are: (1) in patients not requiring dialysis, based on renal response after 3 cycles as the main endpoint, to show a benefit of 30% in absolute rate from an expected 30% response rate in the control arm; and (2) in patients requiring hemodialysis, using the prevalence of patients free of dialysis after 3 cycles as the main endpoint, to show a benefit of at least 20% from an assumed rate of 50% in the control arm. A total sample size of 284 patients was computed to be enrolled (type I and II error rates at 5 and 20%, respectively).

Interventions

  • Drug: Cyclophosphamide + Bortezomib + Dexamethasone regimen
    • Dosing regimen (21 day-cycle): Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required. Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12. Cyclophosphamide 900 mg/m2 on day 1, through a short I.V. infusion The regimen is given for 3 cycles in the absence of serious side-effect.
  • Drug: Bortezomib +Dexamethasone regimen
    • Dosing regimen (21 day-cycle): Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required. Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12. The regimen is given for 3 cycles in the absence of serious side-effect.
  • Device: HCO group
    • TheraliteTM dialyzer of 2.1 m2 in surface
  • Device: conventional high-flux dialyzer
    • conventional high-flux dialyzer; polyacrylonitrile, polysulfone, or PMMA dialysers, with an ultrafiltration coefficient > 14 ml/min and ≥ 1.8 m2 in surface, are recommended.

Arms, Groups and Cohorts

  • Active Comparator: BD
  • Experimental: C-BD
  • Experimental: HCO
  • Active Comparator: Control HD

Clinical Trial Outcome Measures

Primary Measures

  • Prevalence of renal response (if dialysis not mandatory at baseline: strata 1); Prevalence of patients free of dialysis (if dialysis required at baseline; strata 2)
    • Time Frame: 3 months after randomization
    • renal response is defined by creatinine≤ 170 µmol/l and/or DFG (modified MDRD) ≥ 40 ml/min/1.73m2 the absence of any dialysis requirement will be defined by an eDFG > 15 ml/min/1.73 m2, 15 days after the last hemodialysis session

Secondary Measures

  • Improvement in renal function
    • Time Frame: after 1 cycle of chemotherapy, at the end of chemotherapy, at 6 months and 1 year
    • DFG (modified MDRD) hemodialysis requirement
  • Hematological response
    • Time Frame: after 1 and 3 courses, at the end of chemotherapy and at 1 year
    • Partial Response (PR) Very Good Partial Response (VGPR) Complete Response (CR)
  • Progression free survival (PFS)
    • Time Frame: 4 years
    • Time to progression, relapse or death from randomization
  • Time to treatment Failure (TTF)
    • Time Frame: 4 years
    • Time from randomization to progression, relapse, non scheduled hematological treatment or death
  • Overall survival (OS)
    • Time Frame: 4 years
    • Time to death from randomization

Participating in This Clinical Trial

Inclusion Criteria

  • Age >=18 years old – Serum creatinine > 170µmol/l and/or DFG < 40 ml/min/1.73 m2 – Myeloma cast nephropathy (MCN) – Multiple myeloma – Informed consent – neutrophils >= 1 Giga/L and platelets >= 70 Giga/L Exclusion Criteria:

  • Amylosis – Chronic renal Failure with eDFG < 30 ml/min/1.73 m2, unrelated to myeloma – Peripheral neuropathy – Contraindications to either corticosteroids or Bortezomib – Patient refusal – Known HIV infection – Concomitant severe disease including neoplasias (except basocellular carcinoma) – Liver failure, cytolysis, and/or cholestasis – Fertile women who refuse or cannot use effective contraception; Women pregnant or nursing; Women with positive test pregnancy (test before treatment initiation)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Assistance Publique – Hôpitaux de Paris
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jean-Paul Fermand, MD, Principal Investigator, Hôpital saint Louis, Paris, France
    • Franck Bridoux, MD, PhD, Study Director, CHU Poitiers

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.